Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000196944 | SCV000250296 | uncertain significance | not provided | 2015-01-07 | criteria provided, single submitter | clinical testing | p.Pro1623Ala (CCT>GCT): c.4867 C>G in exon 37 of the FBN2 gene (NM_001999.3) The P1623A variant has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. The P1623A variant was not observed with any significant frequency in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The P1623A variant is a semi-conservative amino acid substitution, which may impact secondary protein structure as these residues differ in some properties. This substitution occurs within the TGF-beta binding 6 domain at a position that is conserved in mammals. However, in silico analysis is inconsistent in its predictions as to whether or not the variant is damaging to the protein structure/function. Furthermore, no missense mutations in nearby residues have been reported in association with CCA, suggesting that this region of the protein is tolerant of change. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic mutation or a rare benign variant. This variant was found in TAADV2-1,FBN2 |
Invitae | RCV000819761 | SCV000960440 | likely benign | Congenital contractural arachnodactyly | 2022-12-06 | criteria provided, single submitter | clinical testing |